Drugging the Master Regulator TP53 in Cancer: Mission Possible?-Reference-Cited by-同舟云学术

Drugging the Master Regulator TP53 in Cancer: Mission Possible?

Published:2021-05-10 Issue:14 Volume:39 Page:1595-1597
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Blandino Giovanni¹^ORCID

Affiliation:

1. Oncogenomic and Epigenetic Unit, Department of Research, Advanced Diagnostic and Technological Innovation, Regina Elena National Cancer Institute, Rome, Italy

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.21.00192

Reference16 articles.

1. p53: 800 million years of evolution and 40 years of discovery

2. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome

3. Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

4. An open-label phase I dose-finding study of APR-246 in hematological malignancies

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome;Clinical Lung Cancer;2023-07

2. Activated KRAS, polyamines, iASPP and TME: a multiple liaison in pancreatic cancer;Cell Death & Differentiation;2023-04-29

3. A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions;Molecular Cancer;2022-07-22

4. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia;Cancer;2022-05-25

5. Therapeutic inhibition of GAS6-AS1/YBX1/MYC axis suppresses cell propagation and disease progression of acute myeloid leukemia;Journal of Experimental & Clinical Cancer Research;2021-11-09